Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LNTHBearishIndustry Newsnews

High materiality7/10

FDA CRL Delays LNTH-2501 NDA on Third-Party Manufacturing Issues

Jun 26, 2026, 4:04 PM EDT3 sourcesAI-analyzed

Why it may matterVerify against the original reporting

CRL delays potential LNTH-2501 approval, creating near-term downside risk despite no data concerns; history shows such regulatory obstacles can knock 5-15% off small/mid-cap biotech names until remediation progresses.

AI summary

What happened, with direct paths to the underlying reporting

An FDA Complete Response Letter for LNTH-2501 cites unresolved third-party manufacturing conditions, causing a delay beyond the June 29, 2026 PDUFA date. The agency found no data or safety concerns. Lantheus will work with the partner and FDA to address facility issues and pursue a potential NDA resubmission, preserving LNTH-2501's clinical promise.

FDA issues CRL for LNTH-2501 NDA due to third-party manufacturing. Data safety not questioned.
No data or safety concerns identified for LNTH-2501.
CEO stresses confidence and manufacturing partner remediation only.
LNTH-2501 is a two-vial Ga-68 edotreotide PET kit; not approved.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.